Figure 5: GSf- and GSr-like RPPA endpoints ability to predict TCGA patient survival.
From: Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome
Table plots of hazard ratios (HR) for expression levels of individual RPPA analytes, selected as distinctive of GSf- (A) and GSr-like (B) groups. For each RPPA endpoint, a Cox regression model was applied using the intensity levels (z score) and the subtyping as covariates. In order to generate a multi-gene prognostic index (mPI), the full selection of either GSf- (C) or GSr-like (D) RPPA analytes were included as covariates in a Cox model and table plots of corresponding hazard ratios are shown. Confidence intervals (95% CI) are reported for all HR together with logrank test p values and, for A and B, p values for the RPPA levels. The cohort of patients used for performing Cox survival analyses includes all TCGA patients with known Verhaak subtype (n = 111).
